Drug Therapy in Acute Heart Failure and Cardiogenic Shock
A practical framework for matching acute heart-failure and cardiogenic-shock medications to congestion, perfusion, and patient-specific risks.
Assess and Perfusion Separately
Two questions, not one
Acute heart failure assessment starts with two related but distinct questions: Is the patient congested? and Are the organs being adequately perfused? refers to excess filling pressures and fluid; means insufficient blood flow to organs. A patient can be congested without shock, have shock without marked , or have both. Therefore, the diagnosis alone does not determine the drug strategy.
Treatment aims to relieve , maintain adequate arterial pressure and cardiac output, and restore organ perfusion—without provoking excessive tachycardia, ischemia, or arrhythmia. In shock, a around 65 mm Hg or higher is a common initial reference, not a universal treatment target. Blood pressure is only one part of the picture: an acceptable reading does not prove that organs are receiving enough blood flow.
Reassess the response
Look for changes across several findings: mental status; skin temperature and capillary refill; urine output; lactate trend; kidney and liver function; heart rhythm; and blood pressure. Urine output below about 0.5 mL/kg/h, or an elevated or rising lactate, can signal . These findings are interpreted together and over time, rather than as isolated proof of a particular problem.
For example, if pressure appears adequate but the patient remains confused, has cool skin, or has low urine output, the pressure reading alone is not reassuring. Conversely, treatment should not be driven by a single abnormal measurement without considering the whole clinical response. Frequent reassessment helps identify whether is improving while perfusion remains adequate. If the response is unclear or shock persists, invasive hemodynamic assessment may help guide treatment.
Relieve Without Sacrificing Perfusion
Diuretics: remove excess sodium and water
When acute heart failure includes significant fluid overload, intravenous (IV) loop diuretics such as furosemide are first-line pharmacologic decongestive therapy. By inhibiting the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle, they increase sodium and water excretion. The goal is to reduce clinical , not simply to produce urine, while preserving organ perfusion.
If the response is inadequate, clinicians may increase the IV loop-diuretic regimen or add a thiazide-type diuretic for . Whether decongestion is effective is judged alongside symptoms and signs of , intake and output, and daily weight—not by urine production alone.
Monitoring matters because excessive diuresis can cause volume depletion, low blood pressure, electrolyte disturbances, and worsening kidney function. Follow blood pressure, kidney function, and electrolytes, especially potassium, magnesium, and sodium. A small rise in creatinine during effective decongestion does not, by itself, mean diuresis must stop: consider it alongside remaining and evidence of perfusion. In shock, removing fluid can reduce preload and further impair cardiac output, so the pace of decongestion must be balanced against that risk.
Vasodilators: reduce filling pressures or afterload
Nitroglycerin mainly dilates veins at lower doses, reducing venous return and cardiac filling pressures; at higher doses it also dilates arteries. Sodium nitroprusside is a potent nitric-oxide-mediated arterial and venous that can reduce afterload and preload. Either may be considered as an adjunct to diuretics for dyspnea and pulmonary when systemic blood pressure is adequate.
That condition is important: vasodilation can lower pressure and worsen perfusion. These drugs are generally unsuitable in hypotension or shock when there is not enough pressure to tolerate that effect. Treatment is titrated to symptoms, blood pressure, and, when available, hemodynamics, while watching for hypotension and worsening perfusion. Nitroprusside requires continuous blood-pressure monitoring; prolonged or high-rate exposure can cause cyanide toxicity, and thiocyanate accumulation is a concern particularly when renal clearance is impaired.
Support Cardiac Output and Arterial Pressure
Match the drug's role to the problem
Inotropes and vasopressors address different hemodynamic needs. An supports cardiac contractility and may be used in when low cardiac output is compromising systemic perfusion or end-organ function. A supports arterial pressure when hypotension is clinically important. One patient may need pressure support, output support, or both, depending on the response.
Inotropes: dobutamine and milrinone
Dobutamine mainly stimulates β₁ receptors, with β₂ activity. It increases contractility and often heart rate; its β₂-mediated vasodilation can lower systemic vascular resistance and blood pressure. Thus, it may support low output, but can also worsen hypotension and provoke arrhythmias.
Milrinone inhibits phosphodiesterase-3, increasing intracellular cyclic AMP and producing both inotropy and vasodilation. This combination is sometimes described as an “inodilator” effect. By lowering vascular resistance, milrinone can also worsen hypotension. It is cleared by the kidneys and has a longer effective half-life than dobutamine, so impaired or changing kidney function warrants particular caution.
There is no established universal preference between these agents. Selection depends on blood pressure, rhythm, renal function, recent beta-blocker exposure, and the hemodynamic profile. For either drug, monitor ECG and heart rate, blood pressure, perfusion, and renal function; correct electrolyte abnormalities that increase arrhythmia risk. Inotropes can increase myocardial oxygen demand and provoke tachyarrhythmias or ischemia, so the general principle is the lowest effective dose for the shortest necessary time.
Vasopressors: pressure support is not the whole outcome
For clinically important hypotension in , norepinephrine is a reasonable first-choice for many patients. Its predominant α₁ effect causes vasoconstriction, raising vascular resistance and pressure; β₁ activity may support contractility. If pressure support alone does not correct low output, an may also be needed. Vasopressin may be used as an adjunct in selected cases.
Phenylephrine, a pure α₁ agonist, can increase afterload and reflexively slow the heart, potentially reducing cardiac output. For that reason, it is generally discouraged as sole first-line continuous therapy in . With support, monitor blood pressure when indicated, rhythm, extremity perfusion, urine output, and lactate. Check a norepinephrine infusion site frequently because extravasation can injure tissue; excessive vasoconstriction can also impair peripheral or visceral perfusion. A higher is not enough if organ perfusion is not improving.
Match Treatment to the Whole Hemodynamic Picture
Apply the combined findings
Consider two contrasting patterns. A patient with pulmonary edema, marked hypertension, and preserved perfusion may benefit from IV loop diuresis and a carefully titrated . Here, is prominent, and the blood pressure can tolerate vasodilation; the response still needs to be monitored for falling pressure or worsening perfusion.
Now consider a patient who is cool, confused, oliguric, hypotensive, and congested. These findings raise concern for impaired perfusion as well as . The initial priority is to support pressure and output—often with norepinephrine and, if low output persists, an —while reassessing whether and how quickly to decongest. Removing fluid too aggressively could reduce preload and further impair output, but also remains a problem to address.
The contrast shows why the medication strategy follows the patient’s and perfusion findings, not the acute-heart-failure label alone. Reassess frequently: a change in pressure or urine output matters in context, and a higher pressure does not by itself demonstrate recovery of organ perfusion. If shock persists or worsens despite initial drug therapy, urgent specialist evaluation and consideration of escalation, including temporary mechanical circulatory support, are warranted. Vasoactive drugs should be used at the lowest effective intensity for the shortest necessary time, with escalation of care when perfusion does not recover.
: A medicine that increases sodium and water excretion by inhibiting the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle.